Scholars@Duke
Michael John Kelley

Michael John Kelley

Professor of Medicine
Medicine, Medical Oncology
michael.kelley@duke.edu
Duke Box 3396, Durham, NC 27710
508 Fulton St; Hem-Onc 111G, Durham, NC 27705

Selected Publications

Quality of Care in Veterans Affairs Health Care System In-Person and National TeleOncology Service-Delivered Care.

Journal Article JCO oncology practice · April 2025 PurposeThe Veterans Affairs Health Administration (VA) has experience using telehealth (TH) to deliver care to 10 million enrolled Veterans for many clinical care needs. The VA National TeleOncology Service (NTO) was established in 2020 to provide ... Full text Cite

Summary and Roadmap of Breast Cancer Research in the Veterans Affairs.

Journal Article Military medicine · January 2025 Women are the largest growing population of Veterans within the U.S. Department of Veterans Affairs (VA) Health Care System. Among women Veterans, breast cancer is the most common malignancy (30% of all cancers), yet little is known about the unique needs ... Full text Cite

The Landscape of Care for Women Veterans with Cancer: An Evidence Map.

Journal Article Journal of general internal medicine · September 2024 BackgroundWomen are the fastest growing veteran group in the US and the number of women veterans (WVs) with cancer is rising; however, little is known about this population. Cancer care for WVs is complex and it is essential to understand their un ... Full text Cite

Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer.

Journal Article Eur Urol Oncol · August 2024 BACKGROUND: An electronic health record-based tool could improve accuracy and eliminate bias in provider estimation of the risk of death from other causes among men with nonmetastatic cancer. OBJECTIVE: To recalibrate and validate the Veterans Aging Cohort ... Full text Link to item Cite

The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer.

Journal Article Cancer Immunol Immunother · July 2, 2024 PURPOSE: In advanced non-small cell lung cancer (NSCLC), immune checkpoint inhibitor (ICI) monotherapy is often preferred over intensive ICI treatment for frail patients and those with poor performance status (PS). Among those with poor PS, the additional ... Full text Link to item Cite

Teleoncology in the Veterans Health Administration: Models of Care and the Veteran Experience.

Journal Article Am Soc Clin Oncol Educ Book · June 2024 The Veterans Health Administration (VHA) has pioneered teleoncology to address access challenges faced by Veterans requiring cancer care. This ASCO Educational Book highlights the development of teleoncology programs within the VHA: the local VA Pittsburgh ... Full text Link to item Cite

Telehealth Research and Innovation for Veterans with Cancer: the THRIVE Center.

Journal Article Journal of the National Cancer Institute. Monographs · June 2024 BackgroundIn recent years the US health-care system has witnessed a substantial increase in telehealth use. Telehealth enhances health-care access and quality and may reduce costs. However, there is a concern that the shift from in-person to teleh ... Full text Cite

Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated NSCLC.

Journal Article JTO Clin Res Rep · May 2024 INTRODUCTION: The KRAS G12C inhibitor sotorasib was approved for treating advanced NSCLC in the second line or later on the basis of the CodeBreaK100 trial. Nevertheless, data on the real-world efficacy and safety of sotorasib, and to its optimal dose, rem ... Full text Link to item Cite

Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials.

Conference The oncologist · April 2024 BackgroundSince the onset of COVID-19, oncology practices across the US have integrated telemedicine (TM) and remote patient monitoring (RPM) into routine care and clinical trials. The extent of provider experience and comfort with TM/RPM in treat ... Full text Cite

Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).

Journal Article Pharmacogenomics J · March 4, 2024 The objective of this study was to discover clinical and pharmacogenetic factors associated with bevacizumab-related gastrointestinal hemorrhage in Cancer and Leukemia Group B (Alliance) 90401. Patients with metastatic castration-resistant prostate cancer ... Full text Link to item Cite

Summary of Veterans Health Administration Cancer Data Sources.

Journal Article J Registry Manag · 2024 OBJECTIVES: The Veterans Health Administration (VHA) is a leader in generating transformational research across the cancer care continuum. Given the extensive body of cancer-related literature utilizing VHA data, our objectives are to: (1) describe the VHA ... Link to item Cite

Quality of telehealth-provided cancer care in VA

Conference JOURNAL OF CLINICAL ONCOLOGY · 2024 Cite

Impact of Social Determinants of Health and Novel Therapies on the Outcomes of Relapsed and Refractory Diffuse Large B Cell Lymphoma

Conference Blood · November 2, 2023 Introduction:Outcomes for patients with relapsed and refractory diffuse large B cell lymphoma (R/R DLBCL) have improved dramatically with the recent approvals of chimeric antigen recepto ... Full text Cite

Tolerability and Outcomes of Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia in Patients with Severe Renal Dysfunction

Conference Blood · November 2, 2023 Introduction:There is limited data on the outcomes and tolerability of Bruton Tyrosine Kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL) in patients with severe renal dysfun ... Full text Cite

Reply to M.S. Brose et al.

Journal Article JCO Precis Oncol · September 2023 Full text Link to item Cite

Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population.

Journal Article JCO Precis Oncol · September 2023 PURPOSE: Immune checkpoint inhibitors (ICIs) are used for an increasing number of indications across various tumor types, as well as several tumor-agnostic indications in patients with advanced cancer. Although many patients benefit from ICI therapy, other ... Full text Link to item Cite

On-Site Nurse-Led Cancer Genetics Program Increases Cancer Genetic Testing Completion in Black Veterans.

Journal Article JCO Oncol Pract · August 2023 PURPOSE: Telegenetics services can expand access to guideline-recommended cancer genetic testing. However, access is often not distributed equitably to all races and ethnicities. We evaluated the impact of an on-site nurse-led cancer genetics service in a ... Full text Open Access Link to item Cite

Adopting Weight-Based Dosing With Pharmacy-Level Stewardship Strategies Could Reduce Cancer Drug Spending By Millions.

Journal Article Health Aff (Millwood) · July 2023 Immune checkpoint inhibitors, a class of drugs used in approximately forty unique cancer indications, are a sizable component of the economic burden of cancer care in the US. Instead of personalized weight-based dosing, immune checkpoint inhibitors are mos ... Full text Link to item Cite

Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans.

Journal Article Oncologist · June 2, 2023 Black Veterans have higher a incidence of localized and metastatic prostate cancer compared to White Veterans yet are underrepresented in reports of frequencies of somatic and germline alterations. This retrospective analysis of somatic and putative germli ... Full text Link to item Cite

Veterans Health Administration National TeleOncology Service.

Journal Article JCO oncology practice · April 2023 PurposeAs the largest integrated health care system in the United States, the Veterans Health Administration (VA) is a leader in telehealth-delivered care. All 10 million Veterans cared for within the VA are eligible for telehealth. The VA cares f ... Full text Cite

Risk factors of SARS-CoV-2 infection and complications from COVID-19 in lung cancer patients.

Journal Article Int J Clin Oncol · April 2023 BACKGROUND: Identifying lung cancer patients at an increased risk of getting SARS-CoV-2-related complications will facilitate tailored therapy to maximize the benefit of anti-cancer therapy, while decreasing the likelihood of COVID-19 complications. This a ... Full text Link to item Cite

Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans.

Journal Article JCO Precis Oncol · March 2023 PURPOSE: Neurotrophic tyrosine receptor kinase 1-3 (NTRK1-3) gene fusions are found in a broad range of tumor types. Clinical trials demonstrated high response rates to tropomyosin receptor kinase (TRK) inhibitors in NTRK fusion-positive cancers, but few r ... Full text Link to item Cite

Suicide risk following a new cancer diagnosis among Veterans in Veterans Health Administration care.

Journal Article Cancer Med · February 2023 BACKGROUND: Cancer diagnoses are associated with an increased risk for suicide. The aim of this study was to evaluate this association among Veterans receiving Veterans Health Administration (VHA) care, a population that has an especially high suicide risk ... Full text Link to item Cite

Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program.

Journal Article JCO Precis Oncol · February 2023 PURPOSE: Increasing utilization of comprehensive genomic profiling (CGP) and a growing number of targeted agents (TAs) have led to substantial improvements in outcomes among patients with cancer with actionable mutations. We sought to evaluate real-world e ... Full text Link to item Cite

Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program.

Journal Article J Cancer Res Clin Oncol · January 2023 BACKGROUND: Patients with advanced head and neck squamous cell carcinoma (HNSCC) associated with human papillomavirus (HPV) demonstrate favorable clinical outcomes compared to patients bearing HPV-negative HNSCC. We sought to characterize the association b ... Full text Link to item Cite

Genetics professionals are key to the integration of genetic testing within the practice of frontline clinicians.

Journal Article Genetics in medicine : official journal of the American College of Medical Genetics · January 2023 PurposeGenetic tests have become widely available. We sought to understand the use of genetic tests in the practice of frontline clinicians within the United States Department of Veterans Affairs (VA).MethodsWe administered a web-based su ... Full text Cite

Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.

Journal Article PLoS One · 2023 BACKGROUND: Until recently, multi-agent chemotherapy (CT) was the standard of care for patients with advanced non-small cell lung cancer (NSCLC). Clinical trials have confirmed benefits in overall survival (OS) and progression-free survival with immunother ... Full text Link to item Cite

Success of Liquid Tumor Biopsy in Men with Metastatic Prostate Cancer According to Self-Identified Race

Conference INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS · 2023 Cite

Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.

Journal Article JAMA Oncol · November 1, 2022 IMPORTANCE: Extended-interval dosing of pembrolizumab (400 mg every 6 weeks) was approved by US Food and Drug Administration (FDA) in April 2020 as an alternative to standard-interval dosing (200 mg every 3 weeks). Extended-interval dosing may enhance acce ... Full text Link to item Cite

Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization.

Journal Article Oncologist · August 13, 2022 In the context of cancer, whether or not to choose pregnancy termination represents a difficult and multifaceted decision. In this editorial, members of The Oncologist editorial team attempt to contextualize the potential implications of the recent Supreme ... Full text Link to item Cite

De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer.

Journal Article Eur J Cancer · August 2022 BACKGROUND: One year of adjuvant durvalumab following concurrent chemoradiotherapy significantly improves progression-free survival (PFS) and overall survival (OS) for patients with stage III non-small cell lung cancer (NSCLC). However, the optimal length ... Full text Link to item Cite

Reply to B.L. King-Kallimanis et al.

Journal Article JCO Clin Cancer Inform · July 2022 Full text Link to item Cite

Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now.

Journal Article JCO Oncol Pract · June 2022 PURPOSE: Increased access and utilization of tumor profiling of cancers in our veteran population uncovered a modest number of potentially pathogenic germline variants (PPGVs) that require genetics referral for follow-up evaluation and germline sequencing. ... Full text Link to item Cite

Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program.

Journal Article Semin Oncol · June 2022 Lung cancer is the leading cause of cancer mortality in men and women. Genomic sequencing of non-small cell lung cancer (NSCLC) is critical for the optimal treatment of NSCLC. In this study we sought to describe the frequencies of highly actionable driver ... Full text Link to item Cite

Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma.

Journal Article Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · April 2022 ObjectivesA cost-effectiveness analysis comparing comprehensive genomic profiling (CGP) of 10 oncogenes, targeted gene panel testing (TGPT) of 4 oncogenes, and no tumor profiling over the lifetime for patients with metastatic lung adenocarcinoma f ... Full text Cite

Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors.

Journal Article JCO Precis Oncol · April 2022 PURPOSE: Poly ADP-ribose polymerase inhibitors (PARPi) are used for patients with advanced prostate cancer bearing alterations in homologous recombination repair (HRR) genes. We sought to characterize HRR gene variants and describe real-world outcomes for ... Full text Link to item Cite

Integration of Patient-Reported Outcome Measures in the Electronic Health Record: The Veterans Affairs Experience.

Journal Article JCO Clin Cancer Inform · February 2022 PURPOSE: There are growing efforts to integrate patient-reported outcome (PRO) data into electronic health records (EHRs) to bring together disparate sources of patient information and improve medical care. PRO measures can be used to assess cancer symptom ... Full text Link to item Cite

Metastatic bulk to predict subclonal heterogeneity by ctDNA in RAS/RAF-wildtype colorectal cancer.

Conference Journal of Clinical Oncology · February 1, 2022 186 Background: Distinct molecular subgroups of colorectal cancer (CRC) have been afforded with use of next-generation sequencing (NGS) as standard in clinical practice for advanced disease. We have previously demonstrated that d ... Full text Cite

Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer.

Journal Article Cancers (Basel) · January 26, 2022 One year of durvalumab following concurrent chemoradiotherapy improves progression-free (PFS) and overall survival (OS) for patients with stage III non-small cell lung cancer (NSCLC). However, the real-world efficacy of durvalumab has not been determined. ... Full text Link to item Cite

Recommendation on Advanced Molecular Testing in Hematolymphoid Malignancies in the Veterans Population

Conference Blood · November 5, 2021 AbstractThe Veterans Health Administration is the largest integrated provider of cancer services in the nation, with approximately 50,000 new cancer cases diagnosed each year. The goal of the VA's National O ... Full text Cite

Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites.

Journal Article Pharmacogenomics · November 2021 Aim: The first Plan-Do-Study-Act cycle for the Veterans Affairs Pharmacogenomic Testing for Veterans pharmacogenomic clinical testing program is described. Materials & methods: Surveys evaluating implementation resources and processes were distributed to i ... Full text Link to item Cite

Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer.

Journal Article BMC Cancer · July 16, 2021 BACKGROUND: The Veterans Health Administration (VHA) is the largest integrated health care system in the United States (US). Among VHA patients, the rate of use of concurrent chemoradiation therapy (CCRT) among those with unresectable, stage III non-small ... Full text Link to item Cite

Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program.

Conference JCO Oncol Pract · July 2021 PURPOSE: Next-generation sequencing (NGS) gene panels are frequently completed for patients with advanced non-small-cell lung cancer (NSCLC). Patients with highly actionable gene variants have improved outcomes and reduced toxicities with the use of corres ... Full text Link to item Cite

Real-world outcomes among prostate cancer patients with BRCA2 gene variants compared to variants in other homologous DNA repair genes.

Conference Journal of Clinical Oncology · May 20, 2021 e17033 Background: PARP inhibitors (PARPis) were approved by the FDA for the treatment of advanced prostate cancer (PC) among patients (pts) harboring mutations in genes responsible for homologous DNA repair. Increasing evidence ... Full text Cite

Cancer specialists in the VA as early adopters of clinical genetic services.

Conference Journal of Clinical Oncology · May 20, 2021 11029 Background: Genetic testing has become essential to delivery of cancer treatment, risk assessment, surveillance, and prevention. We sought to understand the use of genetic tests by clinicians in the Department of Veterans A ... Full text Cite

Suicide risk following a new cancer diagnosis among veterans in Veterans Health Administration care.

Conference Journal of Clinical Oncology · May 20, 2021 12130 Background: Patients diagnosed with cancer are at an increased risk of adverse mental health outcomes including suicidal behavior. Suicide rates among Veterans are 50 percent greater than for non-Veteran US adults. To infor ... Full text Cite

Transportation as a barrier to colorectal cancer care.

Journal Article BMC Health Serv Res · April 13, 2021 BACKGROUND: Transportation barriers limit access to cancer care services and contribute to suboptimal clinical outcomes. Our objectives were to describe the frequency of Veterans reporting and the factors associated with transportation barriers to or from ... Full text Open Access Link to item Cite

Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program.

Journal Article Pharmacogenomics · February 2021 In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approximately 5 ... Full text Link to item Cite

EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer.

Journal Article Cancer Treat Res Commun · 2021 BACKGROUND: Epidermal growth factor receptor (EGFR) mutation testing is recommended in metastatic non-small cell lung cancer (NSCLC). The objective of this study was to assess changes in EGFR mutation testing patterns and tyrosine kinase inhibitor (TKI) us ... Full text Link to item Cite

TARGETING SMARCBi IN PEDIATRIC CHORDOMA DEVELOPMENT

Conference ONCOLOGY NURSING FORUM · 2021 Cite

Uptake of KRAS Testing and Anti-EGFR Antibody Use for Colorectal Cancer in the VA.

Journal Article JCO Precis Oncol · 2021 UNLABELLED: Advances in precision oncology, including RAS testing to predict response to epidermal growth factor receptor monoclonal antibodies (EGFR mAbs) in colorectal cancer (CRC), can extend patients' lives. We evaluated uptake and clinical use of KRAS ... Full text Link to item Cite

VA National Precision Oncology Program.

Journal Article Fed Pract · August 2020 BACKGROUND: The US Department of Veterans Affairs (VA) is the largest integrated health care system in the US. The VA sees about 50,000 new cancer diagnoses each year and provides care for more than 400,000 veterans with cancer. The heterogeneity of molecu ... Full text Link to item Cite

Abstract PR11: Racial differences in characteristics of early- vs. late-onset colorectal cancer among veterans

Conference Cancer Epidemiology, Biomarkers & Prevention · June 1, 2020 AbstractIntroduction: Colorectal cancer (CRC) accounts for approximately 8% of annual cancer cases in the Veterans Health Administration. While CRC incidence is decreasing, evidence suggests that the inciden ... Full text Cite

Racial Differences in Treatment and Survival among Veterans and Non-Veterans with Stage I NSCLC: An Evaluation of Veterans Affairs and SEER-Medicare Populations.

Journal Article Cancer Epidemiol Biomarkers Prev · January 2020 BACKGROUND: Surgery is the preferred treatment for stage I non-small cell lung cancer (NSCLC), with radiation reserved for those not receiving surgery. Previous studies have shown lower rates of surgery among Blacks with stage I NSCLC than among Whites. ME ... Full text Link to item Cite

Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis.

Journal Article J Natl Compr Canc Netw · January 2020 BACKGROUND: Adjuvant chemotherapy (AC) after chemoradiation (CRT) and surgery for locoregionally advanced rectal cancer (LARC) is a standard of care in the United States. This study examined the role, optimal regimen, and duration of AC using data from the ... Full text Link to item Cite

Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program.

Journal Article JCO Precis Oncol · 2020 PURPOSE: Next-generation sequencing (NGS) multigene panel testing has become widespread, including the Veterans Affairs (VA), through the VA National Precision Oncology Program (NPOP). The interpretation of genomic alterations remains a bottleneck for real ... Full text Link to item Cite

Medical oncologists' perspectives of the Veterans Affairs National Precision Oncology Program.

Journal Article PLoS One · 2020 BACKGROUND: To support the rising need for testing and to standardize tumor DNA sequencing practices within the U.S. Department of Veterans Affairs (VA)'s Veterans Health Administration (VHA), the National Precision Oncology Program (NPOP) was launched in ... Full text Link to item Cite

An NLP tool to identify molecular diagnostic testing in veterans with stage IV NSCLC.

Conference Journal of Clinical Oncology · September 20, 2019 318 Background: ASCO Quality Oncology Practice Initiative (QOPI) encourages hospitals to determine if patients (pts) with stage IV NSCLC adenocarcinoma have activating EGFR mutations. Guidelines recommend tumor testing to identif ... Full text Cite

National Trends in End-of-Life Care for Veterans With Advanced Cancer in the Veterans Health Administration: 2009 to 2016.

Journal Article J Oncol Pract · June 2019 PURPOSE: It is imperative to provide quality end-of-life (EOL) care for patients with cancer. Although rates of hospice use within the Veterans Health Administration have improved, antineoplastic administration and intensive care unit (ICU) admission at th ... Full text Link to item Cite

Genomic analysis of metastatic solid tumors in veterans: Findings from the VHA National Precision Oncology Program.

Conference Journal of Clinical Oncology · May 20, 2019 3074Background: Scalable next generation sequencing (NGS) technologies have enabled incorporation of precision oncology into ... Full text Cite

Implementation of the VA Symptom Assessment Scale (VSAS): Five-year experience.

Conference Journal of Clinical Oncology · May 20, 2019 e23120 Background: Cancer patients experience symptoms which may precede diagnosis, occur during therapy, and persist into survivorship. Symptom assessments and patient reported outcomes have been shown to improve quality of life ... Full text Cite

Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration.

Journal Article Int J Radiat Oncol Biol Phys · March 1, 2019 PURPOSE: Standard therapy for locally advanced rectal cancer includes neoadjuvant chemoradiation and surgery. Complete response (CR) rates after chemoradiation can be as high as 29%, suggesting that nonoperative management (NOM) may be reasonable with appr ... Full text Link to item Cite

The Veterans Health Administration Precision Oncology Program for Advanced Prostate Cancer Patients: Expanding tumor NGS opportunities to a broader patient population.

Conference Journal of Clinical Oncology · March 1, 2019 193 Background: Progress in understanding molecular changes in advanced prostate cancer has led to promising precision oncology opportunities; to date, most have been concentrated at tertiary research centers and urban centers an ... Full text Cite

Cancer Among Women Treated in the Veterans Affairs Healthcare System.

Journal Article Journal of women's health (2002) · February 2019 BackgroundThe Veterans Affairs (VA) healthcare system is a high-volume provider of cancer care. Women are the fastest growing patient population using VA healthcare services. Quantifying the types of cancers diagnosed among women in the VA is a cr ... Full text Cite

Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry.

Journal Article J Natl Compr Canc Netw · February 2019 Background: Accurate staging for small cell lung cancer (SCLC) is critical for determining appropriate therapy. The clinical impact of increasing PET adoption and stage migration is well described in non-small cell lung cancer but not in SCLC. The objectiv ... Full text Link to item Cite

Cardiovascular disease-related chronic conditions among Veterans Affairs nonmetastatic colorectal cancer survivors: a matched case-control analysis.

Journal Article Cancer Manag Res · 2019 PURPOSE: The growing number of colorectal cancer (CRC) survivors often have multiple chronic conditions. Comparing nonmetastatic CRC survivors and matched noncancer controls, our objectives were to determine the odds of CRC survivors being diagnosed with c ... Full text Open Access Link to item Cite

Genomic Analysis of Metastatic Solid Tumors in Veterans: Findings From the VHA National Precision Oncology Program.

Journal Article JCO Precis Oncol · 2019 PURPOSE: The Veterans Health Administration (VHA) is the largest cancer care provider in the United States, with the added challenge of serving more than twice the percentage of patients with cancer in rural areas than the national average. The VHA establi ... Full text Link to item Cite

Summary of Veterans Health Administration Cancer Data Sources.

Journal Article J Registry Manag · 2019 OBJECTIVES: The Veterans Health Administration (VHA) is a leader in generating transformational research across the cancer care continuum. Given the extensive body of cancer-related literature utilizing VHA data, our objectives are to: (1) describe the VHA ... Link to item Cite

Modeling and Prediction of SIB Prostate IMRT Plans

Conference International Journal of Radiation Oncology*Biology*Physics · November 2018 Full text Cite

National trends in end of life care for veterans with advanced cancer.

Conference Journal of Clinical Oncology · October 20, 2018 3 Background: It is imperative to provide quality end of life (EOL) care for cancer patients. This entails minimizing aggressive measures at the EOL. Although rates of hospice utilization within the Veteran’s Health Administratio ... Full text Cite

Preventing Hepatitis B Reactivation During Anti-CD20 Antibody Treatment in the Veterans Health Administration.

Journal Article Hepatol Commun · September 2018 Hepatitis B virus (HBV) reactivation may occur with high risk immunosuppression, such as anti-cluster of differentiation (CD)20 antibodies (Abs). Appropriate HBV prophylaxis during anti-CD20 Ab therapy averts hepatitis, chemotherapy disruption, and death. ... Full text Open Access Link to item Cite

Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions.

Journal Article Dig Dis Sci · May 2018 Colorectal cancer (CRC) accounts for ~9% of all cancers in the Veteran population, a fact which has focused a great deal of the attention of the VA's research and development efforts. A field-based meeting of CRC experts was convened to discuss both challe ... Full text Link to item Cite

Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.

Journal Article Clin Breast Cancer · April 2018 INTRODUCTION: Ensuring guideline-concordant cancer care is a Department of Veterans Affairs (VA) priority, especially as the number of breast cancer patients at VA medical centers (VAMCs) grows. We assessed the utilization and clinical impact of the 21-gen ... Full text Link to item Cite

Cardiovascular disease-related chronic conditions among Veterans Affairs colorectal cancer survivors: A matched case-control analysis.

Conference Journal of Clinical Oncology · March 1, 2018 4 Background: The growing number of colorectal cancer (CRC) survivors often have multiple chronic conditions. Comparing CRC survivors and matched non-cancer controls, our objectives were to determine the odds of CRC survivors bei ... Full text Cite

Role of adjuvant chemotherapy following chemoradiation and surgery for locoregionally advanced rectal cancer: A Veterans Health Administration analysis.

Conference Journal of Clinical Oncology · February 1, 2018 741 Background: Adjuvant chemotherapy (AC) following chemoradiation (CRT) and total mesorectal excision (TME) for locoregionally advanced rectal cancer (LARC) is a standard of care in the United States despite limited data. The p ... Full text Cite

MYH9 E1841K Mutation Augments Proteinuria and Podocyte Injury and Migration.

Journal Article Journal of the American Society of Nephrology : JASN · January 2018 Intronic variants of the MYH9 gene that encodes the nonmuscle myosin heavy chain IIA are associated with diabetic nephropathy in European Americans and with sickle cell disease-associated nephropathy. However, the causal functional variants of MY ... Full text Cite

Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis.

Journal Article J Thorac Oncol · December 2017 INTRODUCTION: The combined impact of advances in diagnosis and treatment of stage I NSCLC has not been assessed comprehensively. To define the survival impact of modern staging and treatment techniques for clinical stage I NSCLC, the Veterans Administratio ... Full text Link to item Cite

Once Versus Twice Daily Fractionation for Limited Stage SCLC

Conference International Journal of Radiation Oncology*Biology*Physics · October 2017 Full text Cite

Non-operative Management for Locally Advanced Rectal Cancer in the Veterans Health Administration

Conference International Journal of Radiation Oncology*Biology*Physics · October 2017 Full text Cite

Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs.

Journal Article Clin Lung Cancer · July 2017 INTRODUCTION: We examined mutational testing of the epidermal growth factor gene (EGFR) and erlotinib treatment among veterans diagnosed with non-small-cell lung cancer in the United States Department of Veterans Affairs (VA). Our objectives were to identi ... Full text Link to item Cite

Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System: 2010 Update.

Journal Article Mil Med · July 2017 INTRODUCTION: Nearly 50,000 incident cancer cases are reported in Veterans Affairs (VA) Central Cancer Registry (VACCR) annually. This article provides an updated report of cancer incidence recorded in VACCR. MATERIALS AND METHODS: Data were obtained from ... Full text Link to item Cite

Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration.

Journal Article BMC Med Inform Decis Mak · May 30, 2017 BACKGROUND: Current clinical guidelines recommend epidermal growth factor receptor (EGFR) mutational testing in patients with metastatic non-small cell lung cancer (NSCLC) to predict the benefit of the tyrosine kinase inhibitor erlotinib as first-line trea ... Full text Link to item Cite

Short- and long-term outcomes of early stage non-small cell lung cancer (NSCLC) surgery.

Conference Journal of Clinical Oncology · May 20, 2017 8544 Background: The goal of this study was to determine patient factors associated with short- vs long-term survival after surgery for stage I/II NSCLC and assess the distribution of causes of death over time. Methods: Using the ... Full text Cite

Implementation of precision oncology in the Veterans Health Administration (VHA).

Journal Article Journal of Clinical Oncology · May 20, 2017 6507 Background: VHA is the US’s largest integrated healthcare system providing care to over 6 million Veterans (~40% in rural areas). Precision Oncology offers the promise of effective, low-toxicity targeted therapies tailored t ... Full text Cite

Cancer Care Collaborative Approach to Optimize Clinical Care.

Journal Article Fed Pract · May 2017 A collaboration between clinicians and industrial engineers resulted in significant improvements in cancer screening, the development of toolkits, and more efficient care for hepatocellular carcinoma and breast, colorectal, lung, head and neck, and prostat ... Link to item Cite

Implementation of Lung Cancer Screening in the Veterans Health Administration.

Journal Article JAMA Intern Med · March 1, 2017 IMPORTANCE: The US Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose computed tomography for current and former heavy smokers aged 55 to 80 years. There is little published experience regarding implementing this rec ... Full text Link to item Cite

Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Journal Article Cancer Invest · January 2, 2017 The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who unde ... Full text Link to item Cite

BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.

Journal Article Fam Cancer · January 2017 Guideline-concordant cancer care is a priority within the Department of Veterans Affairs (VA). In 2009, the VA expanded its capacity to treat breast cancer patients within VA medical centers (VAMCs). We sought to determine whether male and female Veterans ... Full text Link to item Cite

Colorectal Cancer Statistics From the Veterans Affairs Central Cancer Registry.

Journal Article Clin Colorectal Cancer · December 2016 BACKGROUND: Colorectal cancer (CRC) is a common and potentially deadly disease. Although the United States has robust cancer data reporting, information from the Department of Veterans Affairs (VA) healthcare system has often been underrepresented in natio ... Full text Open Access Link to item Cite

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

Journal Article Clin Cancer Res · October 1, 2016 PURPOSE: Discovery of SNPs that predict a patient's risk of docetaxel-induced neuropathy would enable treatment individualization to maximize efficacy and avoid unnecessary toxicity. The objectives of this analysis were to discover SNPs associated with doc ... Full text Link to item Cite

Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer.

Journal Article J Thorac Oncol · October 2016 INTRODUCTION: Numerous reports suggest lower rates of surgical procedures and poorer survival for black patients with early-stage (stage I or II) NSCLC than for white patients. This study examined treatment trends among blacks and whites with early-stage N ... Full text Link to item Cite

Readiness for Implementation of Lung Cancer Screening. A National Survey of Veterans Affairs Pulmonologists.

Journal Article Ann Am Thorac Soc · October 2016 RATIONALE: To mitigate the potential harms of screening, professional societies recommend that lung cancer screening be conducted in multidisciplinary programs with the capacity to provide comprehensive care, from screening through pulmonary nodule evaluat ... Full text Link to item Cite

Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer.

Journal Article Cancer Epidemiol Biomarkers Prev · October 2016 BACKGROUND: Metformin has been associated with improved colorectal cancer survival, but investigations are limited by small numbers of patients and confounding by diabetic severity. We examined the association between metformin use and overall survival (OS ... Full text Link to item Cite

Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)

Conference Cancer Research · July 15, 2016 AbstractBackground: Treatment-related GI HEM is a major health concern with few known predictive risk factors. The objective of this analysis was to discover clinical and genetic factors that modulate GI HEM ... Full text Cite

Colorectal cancer survivorship statistics: A Veterans Affairs Central Cancer Registry analysis.

Conference Journal of Clinical Oncology · January 20, 2016 e267 Background: Our objective was to evaluate VA CRC incidence and survival and compare with the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) data. Methods: Data were obtained from VACCR for vet ... Full text Cite

Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians.

Journal Article J Cancer Educ · December 2015 Quality improvement measures are uniformly applied to all oncology providers, regardless of their roles. Little is known about differences in adherence to these measures between oncology fellows, advance practice providers (APP), and attending physicians. ... Full text Link to item Cite

A National Survey of Pulmonologists' Views on Low-Dose Computed Tomography Screening for Lung Cancer.

Journal Article Ann Am Thorac Soc · November 2015 RATIONALE: Multiple guidelines now recommend low-dose computed tomography (LDCT) screening for lung cancer. Given their central role in the planning of LDCT screening programs, pulmonologists' beliefs about LDCT screening will affect the safety, cost-effec ... Full text Link to item Cite

Early-Stage Lung Cancer Treatment and Survival: Impact of Race

Journal Article JOURNAL OF THORACIC ONCOLOGY · September 1, 2015 Link to item Cite

Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer.

Journal Article Cancer · August 1, 2015 BACKGROUND: Adjuvant chemotherapy after surgical resection improves outcomes for patients with early-stage non-small cell lung cancer (NSCLC). To the authors' knowledge, there are no published prospective trials to date of adjuvant chemotherapy after surgi ... Full text Link to item Cite

Utilization of BRCA1/BRCA2 testing in Veterans Health Administration.

Conference Journal of Clinical Oncology · May 20, 2015 Full text Cite

Comparing a medical records-based and a claims-based index for measuring comorbidity in patients with lung or colon cancer.

Journal Article J Geriatr Oncol · May 2015 OBJECTIVE: Ascertaining comorbid conditions in cancer patients is important for research and clinical quality measurement, and is particularly important for understanding care and outcomes for older patients and those with multi-morbidity. We compared the ... Full text Link to item Cite

Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).

Journal Article Cancer · April 1, 2015 BACKGROUND: Bevacizumab is associated with an increased risk of arterial thromboembolism (ATE); however, its effect on venous thromboembolism (VTE) remains controversial. Scant data exist on the factors that increase the risk of ATE/VTE in patients with pr ... Full text Link to item Cite

A preliminary exploration of college smokers' reactions to nicotine dependence genetic susceptibility feedback.

Journal Article Nicotine Tob Res · March 2015 INTRODUCTION: Many young smokers underestimate their risk for becoming addicted to cigarettes. We explored whether informing light college smokers (i.e., fewer than 5 cigarettes/day) of their genetic predisposition to nicotine dependence influenced their p ... Full text Link to item Cite

Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data.

Journal Article J Clin Oncol · February 20, 2015 PURPOSE: The optimal chemotherapy regimen to use with radiotherapy in stage III non-small-cell lung cancer is unknown. Here, we compare the outcome of patents treated within the Veterans Health Administration with either etoposide-cisplatin (EP) or carbopl ... Full text Link to item Cite

Nonmuscle myosin II-A plays a role in sperm development.

Conference MOLECULAR BIOLOGY OF THE CELL · January 1, 2015 Link to item Cite

Adjuvant Chemotherapy for Older Patients With Early-Stage Non-Small Cell Lung Cancer

Conference International Journal of Radiation Oncology*Biology*Physics · November 2014 Full text Cite

Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma.

Journal Article Hum Genet · October 2014 Chordoma is a rare bone cancer that is believed to originate from notochordal remnants. We previously identified germline T duplication as a major susceptibility mechanism in several chordoma families. Recently, a common genetic variant in T (rs2305089) wa ... Full text Link to item Cite

Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines.

Journal Article J Neurosurg Spine · September 2014 OBJECT: Chordoma cells can generate solid-like tumors in xenograft models that express some molecular characteristics of the parent tumor, including positivity for brachyury and cytokeratins. However, there is a dearth of molecular markers that relate to c ... Full text Open Access Link to item Cite

Acting in the face of uncertainty.

Journal Article Ann Intern Med · August 19, 2014 Full text Link to item Cite

Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer.

Journal Article Cancer · July 1, 2014 BACKGROUND: Despite clinical trials demonstrating improved survival with adjuvant chemotherapy (AC) for patients with American Joint Committee on Cancer stages I to III non-small cell lung cancer (NSCLC), it is unclear whether this survival benefit extends ... Full text Link to item Cite

Cancer Incidence in HIV-Infected Versus Uninfected Veterans: Comparison of Cancer Registry and ICD-9 Code Diagnoses.

Journal Article J AIDS Clin Res · July 2014 BACKGROUND: Given the growing interest in the cancer burden in persons living with HIV/AIDS, we examined the validity of data sources for cancer diagnoses (cancer registry versus International Classification of Diseases, Ninth Revision [ICD-9 codes]) and c ... Full text Link to item Cite

Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.

Journal Article J Thorac Oncol · May 2014 BACKGROUND: While platinum-based doublet chemotherapy is standard of care for patients presenting with metastatic non-small-cell lung cancer, the optimal platinum agent (cisplatin versus carboplatin) is unclear. We therefore compared survival and toxicity ... Full text Link to item Cite

Feasibility of using an epigenetic marker of risk for lung cancer, methylation of p16, to promote smoking cessation among US veterans.

Journal Article BMJ Open Respir Res · 2014 INTRODUCTION: Providing smokers feedback using epigenetic markers of lung cancer risk has yet to be tested as a strategy to motivate smoking cessation. Epigenetic modification of Rb-p16 (p16) due to tobacco exposure is associated with increased risk of dev ... Full text Open Access Link to item Cite

Tools to accurately identify veterans who undergo molecular diagnostic testing.

Conference Journal of Clinical Oncology · November 1, 2013 201 Background: Yearly, 52,000 veterans are diagnosed with cancer. Minorities represent 18.5% (9,651) of these patients. The rapid and explosive growth of molecular diagnostics (MDx) has created challenges for large healthcare sy ... Full text Cite

Epigenetic assay detects early stage non-small cell lung cancer in sputum

Journal Article EUROPEAN JOURNAL OF CANCER · November 1, 2013 Link to item Cite

Comparison of QOPI measure conformance between oncology fellows and attending physicians.

Journal Article J Clin Oncol · November 2013 162 Background: Quality improvement measures are uniformly applied to all oncology providers, regardless of their positions. Little is known about differences in conformance to these measures between oncology fellows and attending physicians. In order to t ... Full text Link to item Cite

Identification of repurposed small molecule drugs for chordoma therapy.

Journal Article Cancer Biol Ther · July 2013 Chordoma is a rare, slow growing malignant tumor arising from remnants of the fetal notochord. Surgery is the first choice for chordoma treatment, followed by radiotherapy, although postoperative complications remain significant. Recurrence of the disease ... Full text Link to item Cite

Evolution of the Quality Oncology Practice Initiative supportive care quality measures portfolio and conformance at a Veterans Affairs medical center.

Journal Article Journal of oncology practice · May 2013 PurposeA growing set of quality measures is being implemented to evaluate all components of cancer care, from diagnosis through the end of life. We investigated the Quality Oncology Practice Initiative (QOPI) quality measures portfolio. Additional ... Full text Cite

Abstract 352: Murine model of chordoma: Sonic Hedgehog promoter-driven Cre activation of Brachyury (T) expression induces spinal disk abnormalities and perinatal lethal developmental defects.

Conference Cancer Research · April 15, 2013 AbstractIntroduction: Chordoma is a rare malignancy arising in the axial skeleton from notochord remnants. The T-box transcription factor, Brachyury (T), is associated with familial chordoma, is expressed in ... Full text Cite

Influence of comorbidity on racial differences in receipt of surgery among US veterans with early-stage non-small-cell lung cancer.

Journal Article J Clin Oncol · February 1, 2013 Featured Publication PURPOSE: It is unclear why racial differences exist in the frequency of surgery for lung cancer treatment. Comorbidity is an important consideration in selection of patients for lung cancer treatment, including surgery. To assess whether comorbidity contri ... Full text Link to item Cite

Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.

Journal Article J Thorac Oncol · January 2013 Featured Publication INTRODUCTION: We sought to determine the efficacy of using both irinotecan- and etoposide-containing regimens sequentially for patients with untreated limited-stage small-cell lung cancer. METHODS: Patients with untreated, measurable, limited-stage small-c ... Full text Link to item Cite

Assessment of the impact of adjunctive proactive telephone counseling to promote smoking cessation among lung cancer patients' social networks.

Journal Article Am J Health Promot · 2013 PURPOSE: When a patient is diagnosed with lung cancer, members of his/her social network may be more likely to engage in smoking cessation efforts. Proactive telephone counseling combined with a tailored self-directed intervention may be more effective at ... Full text Link to item Cite

Impact of race on early-stage lung cancer treatment and survival

Journal Article JOURNAL OF CLINICAL ONCOLOGY · December 1, 2012 Full text Link to item Cite

The evolution of supportive care quality measures portfolio and conformance

Journal Article JOURNAL OF CLINICAL ONCOLOGY · December 1, 2012 Full text Link to item Cite

The evolution of supportive care quality measures portfolio and conformance.

Journal Article J Clin Oncol · December 2012 259 Background: A growing set of quality measures is being implemented to evaluate all components of cancer care ranging from diagnosis through the end-of-life (EOL). With an increasing emphasis from ASCO and others on the regular delivery of supportive ca ... Full text Link to item Cite

Persistence of quality improvement in a Veterans Affairs (VA) academic practice assessed by Quality Oncology Practice Initiative (QOPI).

Journal Article J Clin Oncol · December 2012 209 Background: The success of quality improvement (QI) efforts is usually assessed initially within a year of implementation but performance may later decline. We sought to determine the longer-term effectiveness of practice improvement interventions and ... Full text Link to item Cite

Impact of race on early-stage lung cancer treatment and survival.

Journal Article J Clin Oncol · December 2012 232 Background: Studies have documented racial differences along the lung cancer continuum and equity in care is essential to quality improvement. The purpose of this study was to investigate the influence of race on lung cancer treatment and survival amon ... Full text Link to item Cite

Cancer incidence among patients of the U.S. Veterans Affairs Health Care System.

Journal Article Mil Med · June 2012 Featured Publication OBJECTIVE: Approximately 40,000 incident cancer cases are reported in the Veterans Affairs Central Cancer Registry (VACCR) annually (approximately 3% of U.S. cancer cases). Our objective was to provide the first comprehensive description of cancer incidenc ... Full text Link to item Cite

Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.

Journal Article Blood · January 5, 2012 Featured Publication We have generated 3 mouse lines, each with a different mutation in the nonmuscle myosin II-A gene, Myh9 (R702C, D1424N, and E1841K). Each line develops MYH9-related disease similar to that found in human patients. R702C mutant human cDNA fused with green f ... Full text Link to item Cite

Surveillance for hepatocellular carcinoma.

Journal Article Ann Intern Med · August 16, 2011 Full text Link to item Cite

Proactive recruitment of cancer patients' social networks into a smoking cessation trial.

Journal Article Contemp Clin Trials · July 2011 BACKGROUND: This report describes the characteristics associated with successful enrollment of smokers in the social networks (i.e., family and close friends) of patients with lung cancer into a smoking cessation intervention. METHODS: Lung cancer patients ... Full text Link to item Cite

Automated extraction of Quality Oncology Practice Initiative (QOPI) quality measures from the Veterans Health Administration (VHA) electronic health record system.

Journal Article J Clin Oncol · May 20, 2011 e16560 Background: ASCO's QOPI is a program that requires manual data abstraction of medical record data to measure quality of cancer care, a necessary component of quality improvement programs. Improving quality of care for veterans is a long-standing goa ... Link to item Cite

Retraction: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80.

Other N Engl J Med · March 24, 2011 To the Editor: We would like to retract our article, "A Genomic Strategy to Refine Prognosis in Early-Stage Non-Small-Cell Lung Cancer,"(1) which was published in the Journal on August 10, 2006. Using a sample set from a study by the American College of Su ... Full text Link to item Cite

Mouse Models of Human MYH9-Related Diseases

Journal Article Biophysical Journal · February 2011 Full text Cite

Generating laminar, reproducible flow rates by modeling transport properties of the hydrofluoric acid-sulfuric acid mixture

Conference Process Development Division - Core Programming Topic at the 2011 AIChE Annual Meeting · January 1, 2011 The Thomas Jefferson National Accelerator Facility (Jefferson Lab) aims to maximize the performance of particle accelerators by perfecting superconducting radiofrequency (SRF) technology. Smooth niobium interior cavities ensure that electron beams do not s ... Cite

Lung cancer management in 2010.

Journal Article Oncology (Williston Park) · January 2011 The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the ... Link to item Cite

Lung cancer management in 2010.

Journal Article Oncology (Williston Park, N.Y.) · January 1, 2011 The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the ... Cite

Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs.

Journal Article J Clin Oncol · July 1, 2010 PURPOSE: The Veterans Affairs (VA) healthcare system treats approximately 3% of patients with cancer in the United States each year. We measured the quality of nonmetastatic colorectal cancer (CRC) care in VA as indicated by concordance with National Compr ... Full text Link to item Cite

A pathway-based classification of human breast cancer.

Journal Article Proc Natl Acad Sci U S A · April 13, 2010 The hallmark of human cancer is heterogeneity, reflecting the complexity and variability of the vast array of somatic mutations acquired during oncogenesis. An ability to dissect this heterogeneity, to identify subgroups that represent common mechanisms of ... Full text Link to item Cite

Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.

Journal Article J Pathol · April 2010 Currently there is no effective chemotherapy for chordoma. Recent studies report co-expression of insulin-like growth factor-1 receptor (IGF1R) and its cognate ligand in chordoma, but it is unknown whether this receptor tyrosine kinase is activated in thes ... Full text Link to item Cite

Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer.

Journal Article Med Oncol · March 2010 PURPOSE: The prognostic significance of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) expression remains unestablished, although EGFR and COX-2 are frequently overexpressed in non-small cell lung cancer (NSCLC). Considering the impor ... Full text Link to item Cite

A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).

Journal Article J Thorac Oncol · March 2010 INTRODUCTION: SRC is an oncogene with an essential role in the invasiveness and metastasis of solid tumors including small cell lung cancer. Dasatinib is a potent inhibitor of SRC as well as other tyrosine kinases. The primary objective of this study was t ... Full text Link to item Cite

Developing and sustaining quality improvement partnerships in the VA: the Colorectal Cancer Care Collaborative.

Journal Article J Gen Intern Med · January 2010 OBJECTIVE: The Veterans Affairs (VA) Quality Enhancement Research Initiative (QUERI) seeks to develop partnerships between VA health services researchers and clinical managers, with the goal of designing and evaluating interventions to improve the quality ... Full text Link to item Cite

Molecular characterization of putative chordoma cell lines.

Journal Article Sarcoma · 2010 Featured Publication Immortal tumor cell lines are an important model system for cancer research, however, misidentification and cross-contamination of cell lines are a common problem. Seven chordoma cell lines are reported in the literature, but none has been characterized in ... Full text Link to item Cite

T (brachyury) gene duplication confers major susceptibility to familial chordoma.

Journal Article Nat Genet · November 2009 Featured Publication Using high-resolution array-CGH, we identified unique duplications of a region on 6q27 in four multiplex families with at least three cases of chordoma, a cancer of presumed notochordal origin. The duplicated region contains only the T (brachyury) gene, wh ... Full text Link to item Cite

Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.

Journal Article J Thorac Oncol · September 2009 BACKGROUND: In Cancer and Leukemia Group B 39801, we evaluated whether induction chemotherapy before concurrent chemoradiotherapy would result in improved survival and demonstrated no significant benefit from the addition of induction chemotherapy. The pri ... Full text Link to item Cite

Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801.

Journal Article J Clin Oncol · May 20, 2009 7535 Background: CALGB 39801 was designed to test whether treatment with induction chemotherapy and concurrent chemoradiotherapy (arm B) would improve OS in comparison to identical chemoradiotherapy alone (arm A), and demonstrated no significant benefit in ... Link to item Cite

Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels.

Journal Article J Pain · March 2009 UNLABELLED: The purpose of this study was to evaluate the impact of smoking status after a diagnosis of lung cancer on reported pain levels. We conducted a telephone survey of patients with lung cancer identified from 4 participating sites between Septembe ... Full text Link to item Cite

Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice.

Journal Article J Clin Invest · December 2008 Tumors contain oxygenated and hypoxic regions, so the tumor cell population is heterogeneous. Hypoxic tumor cells primarily use glucose for glycolytic energy production and release lactic acid, creating a lactate gradient that mirrors the oxygen gradient i ... Full text Link to item Cite

Improving quality at university based hematology/oncology fellowship continuity clinic with the quality oncology practice initiative (QOPI).

Journal Article J Clin Oncol · May 20, 2008 6578 Background: Quality imporvement is an important component of improving cancer care and is now an ACGME requirement of fellowship training. The feasibility of integrating QI activities into fellowship training is not known. METHODS: The Hematology/Onco ... Link to item Cite

Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition).

Journal Article Chest · September 2007 BACKGROUND: Lung cancer is the most common cause of cancer death in the United States. Cigarette smoking is the main risk factor. Former smokers are at a substantially increased risk for lung cancer compared with lifetime never-smokers. Chemoprevention is ... Full text Link to item Cite

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Journal Article J Clin Oncol · May 1, 2007 Featured Publication PURPOSE: Standard therapy for unresectable stage III non-small-cell lung cancer includes concomitant chemoradiotherapy. In Cancer and Leukemia Group B 39801, we evaluated whether induction chemotherapy before concurrent chemoradiotherapy would result in im ... Full text Link to item Cite

Genomic signatures to guide the use of chemotherapeutics.

Other Nat Med · November 2006 Using in vitro drug sensitivity data coupled with Affymetrix microarray data, we developed gene expression signatures that predict sensitivity to individual chemotherapeutic drugs. Each signature was validated with response data from an independent set of ... Full text Link to item Cite

Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care

Journal Article Journal of Thoracic Oncology · September 2006 Full text Cite

Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care.

Journal Article J Thorac Oncol · September 2006 BACKGROUND: Multidisciplinary clinics have been recommended for the evaluation of patients with lung cancer. Evidence to support this recommendation, however, is limited. A single-center, retrospective review of lung cancer patients at a Veterans Affairs h ... Link to item Cite

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

Journal Article N Engl J Med · August 10, 2006 BACKGROUND: Clinical trials have indicated a benefit of adjuvant chemotherapy for patients with stage IB, II, or IIIA--but not stage IA--non-small-cell lung cancer (NSCLC). This classification scheme is probably an imprecise predictor of the prognosis of a ... Full text Link to item Cite

A genomic strategy to combinatorial therapeutics in solid tumors.

Journal Article J Clin Oncol · June 20, 2006 2031 Background: For most advanced solid tumors, the response rate to cytotoxic drugs is generally low, highlighting the importance of identifying those patients most likely to respond, either to single agents or combinations of cytotoxic or targeted thera ... Link to item Cite

A genomic strategy to refine prognosis in early stage non-small cell lung carcinoma (NSCLC).

Journal Article J Clin Oncol · June 20, 2006 7026 Background. Although stage-specific classification identifies appropriate populations for adjuvant chemotherapy, this is likely an imprecise predictor for the individual patient with early stage NSCLC. METHODS: Using previously-described methodologies ... Link to item Cite

A genomic strategy to combinatorial therapeutics in solid tumors.

Conference JOURNAL OF CLINICAL ONCOLOGY · June 20, 2006 Link to item Cite

Corroboration of a familial chordoma locus on chromosome 7q and evidence of genetic heterogeneity using single nucleotide polymorphisms (SNPs).

Journal Article Int J Cancer · September 1, 2005 Chordoma, a rare bone tumor originating from notochordal remnants, has a genetic predisposition in some families. Previously, we performed linkage analysis using microsatellite (STR) markers on 3 unrelated chordoma kindreds (16 patients with chordoma) and ... Full text Link to item Cite

Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer.

Journal Article Lung Cancer · September 2005 Endogenous hypoxia markers have been studied as prognostic indicators because they appear to be associated with tumor aggressiveness. This study was undertaken to compare the expression of two endogenous hypoxia markers, Hypoxia-inducible factor-1alpha (HI ... Full text Link to item Cite

Genotype-phenotype correlation in MYH9-related thrombocytopenia.

Journal Article Br J Haematol · August 2005 Mutation of the non-muscle myosin heavy chain type II-A results in MYH9-related hereditary macrothrombocytopenia (HMTC), including four autosomal dominant platelet disorders: May-Hegglin anomaly (MHA), Sebastian (SBS), Fechtner (FS) and Epstein (EPS) syndr ... Full text Link to item Cite

Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome.

Journal Article J Clin Oncol · August 1, 2005 PURPOSE: To determine the ability to induce tumor-specific immunity with individual mutant K-ras-or p53-derived peptides and to monitor clinical outcome. PATIENTS AND METHODS: Patients in varying stages of disease underwent genetic analysis for mutations i ... Full text Link to item Cite

Expression of phosphorylated epidermal growth factor receptor (p-EGFR) in early stage non-small cell lung cancer: its relationship with overexpression of EGFR and cyclooxygenase-2 (COX-2), and survival.

Journal Article J Clin Oncol · June 2005 9614 Background: Epidermal growth factor receptor (EGFR) is widely overexpressed in various cancers, and reported to relate with growth and invasion of cancer cells. However, clinical significance of EGFR overexpression is still controversial because its c ... Link to item Cite

Retrospective family study of childhood medulloblastoma.

Journal Article Am J Med Genet A · May 1, 2005 Medulloblastoma is the most common malignant central nervous system tumor of childhood and can occur sporadically or in association with inherited cancer susceptibility syndromes such as the nevoid basal cell carcinoma syndrome (NBCCS). To determine whethe ... Full text Link to item Cite

Safety and efficacy of weekly oral oltipraz in chronic smokers.

Journal Article Cancer Epidemiol Biomarkers Prev · April 2005 Featured Publication Cigarette smoking is thought to contribute to carcinogenesis by formation of DNA adducts of tobacco smoke constituents leading to genotoxic damage. The dithiolethione, oltipraz, is a putative cancer chemopreventive agent that induces phase II detoxifying e ... Full text Link to item Cite

Rod mutations associated with MYH9-related disorders disrupt nonmuscle myosin-IIA assembly.

Journal Article Blood · January 1, 2005 MYH9-related disorders are autosomal dominant syndromes, variably affecting platelet formation, hearing, and kidney function, and result from mutations in the human nonmuscle myosin-IIA heavy chain gene. To understand the mechanisms by which mutations in t ... Full text Link to item Cite

Carbonic anhydrase IX in early-stage non-small cell lung cancer.

Journal Article Clin Cancer Res · December 1, 2004 PURPOSE: Tumor hypoxia is associated with poor prognosis and increased tumor aggressiveness. Carbonic anhydrase (CA) IX, an endogenous marker for tumor hypoxia, catalyzes the hydration of carbon dioxide into carbonic acid and contributes to the pH regulati ... Full text Link to item Cite

Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial.

Journal Article J Clin Oncol · July 15, 2004 7005 Background: Standard therapy for unresectable stage III NSCLC includes concomitant chemoradiotherapy. In CALGB 39801, we evaluated whether the addition of induction chemotherapy prior to CT/XRT would result in improved survival. METHODS: Between 10/19 ... Link to item Cite

Ultrastructural analysis of granulocyte inclusions in genetically confirmed MYH9-related disorders.

Journal Article Haematologica · March 2004 BACKGROUND AND OBJECTIVES: MYH9-related disorders are autosomal dominant hereditary macrothrombocytopenias caused by mutations in the MYH9 gene. This gene encodes the non-muscular myosin heavy chain type II A (MHCIIA). Among these disorders, May-Hegglin an ... Link to item Cite

Molecular classification and molecular genetics of human lung cancers.

Journal Article Semin Oncol · February 2004 Recent advances in the molecular classification of lung carcinomas and the identification of causative genetic alterations will likely lead to improvements in the diagnosis and treatment of patients with lung cancer. It is now possible to identify gene exp ... Full text Link to item Cite

Genetic heterogeneity in familial chordoma

Conference AMERICAN JOURNAL OF HUMAN GENETICS · November 1, 2003 Link to item Cite

Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.

Journal Article Clin Cancer Res · May 2003 OBJECTIVES: Our objective was to test the prognostic importance of both the pretreatment level and change in serum CYFRA 21-1 after one cycle of chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and to compare these two CYFRA variab ... Link to item Cite

Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells.

Journal Article Cancer Chemother Pharmacol · March 2003 PURPOSE: Ritterazine B, one of the ritterazine analogues extracted from Ritterella tokioka, has been shown to be chemically similar to cephalostatin 1, and among the ritterazine derivatives is the most cytotoxic to P388 murine leukemia cells. The objective ... Full text Link to item Cite

Assessment of the scope and quality of clinical practice guidelines in lung cancer.

Journal Article Chest · January 2003 STUDY OBJECTIVES: To provide an evidence-based background for developing the American College of Chest Physicians (ACCP) lung cancer guidelines, a systematic review of the literature was performed to identify published lung cancer guidelines and evaluate t ... Full text Link to item Cite

Prevention of lung cancer: summary of published evidence.

Journal Article Chest · January 2003 STUDY OBJECTIVES: To describe empiric research related to lung cancer prevention strategies, including chemoprevention aimed at reducing lung cancer incidence and various smoking avoidance and cessation interventions aimed at reducing smoking rates. DESIGN ... Full text Link to item Cite

Screening for lung cancer: a review of the current literature.

Journal Article Chest · January 2003 STUDY OBJECTIVES: To review the available data on the early detection of lung cancer, with a focus on three technologies: chest x-ray (CXR), sputum cytology, and low-dose CT (LDCT) scanning. DESIGN, SETTING, PARTICIPANTS: Review of published clinical studi ... Full text Link to item Cite

Screening for lung cancer: A review of the current literature

Journal Article Chest · January 1, 2003 Study objectives: To review the available data on the early detection of lung cancer, with a focus on three technologies: chest x-ray (CXR), sputum cytology, and low-dose CT (LDCT) scanning. Design, setting, participants: Review of published clinical studi ... Full text Cite

Prevention of lung cancer: Summary of published evidence

Journal Article Chest · January 1, 2003 Study objectives: To describe empiric research related to lung cancer prevention strategies, including chemoprevention aimed at reducing lung cancer incidence and various smoking avoidance and cessation interventions aimed at reducing smoking rates. Design ... Full text Cite

Replication of linkage results using MALDI-TOF detection of single nucleotide polymorphisms (SNPS)

Journal Article Proceedings 50th ASMS Conference on Mass Spectrometry and Allied Topics · December 1, 2002 The utility of MALDI-TOF MS detection of single nucleotide polymorphisms (SNP) was discussed. The study was carried out by genotyped and analyzed 40 SNPs on chromosomes 22 using the Homogeneous Mass EXTEND (hME) assay in one large 4 generation family consi ... Cite

Randomized controlled clinical trial of weekly oltipraz in smokers.

Conference CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION · October 1, 2002 Link to item Cite

Re: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer - Response

Journal Article JOURNAL OF THE NATIONAL CANCER INSTITUTE · May 15, 2002 Link to item Cite

Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer.

Journal Article J Natl Cancer Inst · December 19, 2001 Featured Publication Full text Link to item Cite

A familial chordoma locus maps to chromosome 7q33.

Journal Article AMERICAN JOURNAL OF HUMAN GENETICS · October 1, 2001 Link to item Cite

Familial chordoma, a tumor of notochordal remnants, is linked to chromosome 7q33.

Journal Article Am J Hum Genet · August 2001 Chordoma is a rare tumor originating from notochordal remnants that is usually diagnosed during midlife. We performed a genomewide analysis for linkage in a family with 10 individuals affected by chordoma. The maximum two-point LOD score based on only the ... Full text Link to item Cite

Genetic changes in contralateral bronchioloalveolar carcinomas of the lung.

Journal Article Oncology · 2001 OBJECTIVE: The pattern of metastases and recurrence of bronchioloalveolar carcinoma (BAC) differs from adenocarcinoma of the lung, occurring more frequently within the lung without extrapulmonary involvement. Analyses of genetic differences of contralatera ... Full text Link to item Cite

Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9.

Journal Article Am J Hum Genet · November 2000 The authors had previously mapped a new locus-DFNA17, for nonsyndromic hereditary hearing impairment-to chromosome 22q12.2-q13. 3. DFNA17 spans a 17- to 23-cM region, and MYH9, a nonmuscle-myosin heavy-chain gene, is located within the linked region. Becau ... Full text Link to item Cite

Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly.

Journal Article Nat Genet · September 2000 Featured Publication May-Hegglin anomaly (MHA) is an autosomal dominant macrothrombocytopenia of unclear pathogenesis characterized by thrombocytopenia, giant platelets and leukocyte inclusions. Studies have indicated that platelet structure and function are normal, suggesting ... Full text Link to item Cite

Autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly) is linked to chromosome 22q12-13.

Journal Article Hum Genet · May 2000 Macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly) is a rare autosomal dominant disorder characterized by thrombocytopenia, giant platelets, and Döhle body-like inclusions in leukocytes. To determine the genetic basis of this disorder, w ... Full text Link to item Cite

MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma.

Journal Article Genes Chromosomes Cancer · May 2000 Neuroendocrine tumors of the lung consist of a spectrum of neoplasms, including typical carcinoids, atypical carcinoids, large-cell neuroendocrine carcinomas (LCNEC), and small-cell lung carcinomas (SCLC). We previously reported frequent inactivation of th ... Full text Link to item Cite

The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.

Journal Article Clin Cancer Res · December 1999 Loss of p16 functional activity leading to disruption of the p16/cyclin-dependent kinase (CDK) 4:cyclin D/retinoblastoma pathway is the most common event in human tumorigenesis, suggesting that compounds with CDK4 kinase inhibitory activity may be useful t ... Link to item Cite

Genomic screen for linkage of May-Hegglin anomaly.

Journal Article AMERICAN JOURNAL OF HUMAN GENETICS · October 1, 1999 Link to item Cite

Genomic structure of the EPHA1 receptor tyrosine kinase gene.

Journal Article Mol Cell Probes · June 1999 Some receptor tyrosine kinase genes are mutated in inherited and somatically acquired human cancers. To permit mutational analysis, the complete genomic structure of the human EPHA1 gene on chromosome 7q34 was determined and oligonucleotide pairs were desi ... Full text Link to item Cite

Autocrine Growth Factors and Neuroendocrine Markers in the Development of Small-Cell Lung Cancer

Journal Article ONCOLOGY · December 1, 1998 Two different clinical trials using biological agents directed against an autocrine growth factor and a surface marker of neuroendocrine differentiation have been used for patients with relapsed small-cell lung cancer. In a phase II trial, an antibody (2A1 ... Cite

Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.

Journal Article Clin Cancer Res · September 1998 The mammalian pulmonary toxin 4-ipomeanol (IPO) is activated by the cytochrome P450 system in bronchial Clara cells in animals. The resulting metabolites bind rapidly to macromolecules, producing localized cytotoxicity. IPO has in vitro and in vivo antitum ... Link to item Cite

Correlation of expression of bombesin-like peptides and receptors with growth inhibition by an anti-bombesin antibody in small-cell lung cancer cell lines.

Journal Article Lung Cancer · September 1998 The murine anti-bombesin monoclonal antibody, 2A11, has been demonstrated to inhibit growth of some small-cell lung cancer (SCLC) cells in nude mice xenografts and in a clinical trial. To determine if the expression of bombesin-like peptides (BLP) and thei ... Full text Link to item Cite

Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines.

Journal Article Oncogene · August 27, 1998 Specific genetic alterations affecting proto-oncogenes of the myc gene family are frequently detected in human lung cancer. Among 11 SCLC cell lines with L-myc gene amplification, four were found to have alteration of the RLF gene by Southern blot and RT-P ... Full text Link to item Cite

Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer.

Journal Article Oncology (Williston Park) · January 1998 Two different clinical trials using biological agents directed against an autocrine growth factor and a surface marker of neuroendocrine differentiation have been used for patients with relapsed small-cell lung cancer. In a phase II trial, an antibody (2A1 ... Link to item Cite

Purification and molecular cloning of a secreted, frizzled-related WNT antagonist

Journal Article FASEB Journal · December 1, 1997 Frizzled polypeptides are integral membrane proteins that recently were shown to function as receptors for Wnt signaling molecules. Here, we report the identification of a novel, heparin-binding, 36 kDa Frizzled-related protein (FRP) that was purified from ... Cite

Pancreatic panniculitis.

Journal Article J Clin Oncol · November 1997 Full text Link to item Cite

Fluorescence in situ hybridization analysis of keratinocyte growth factor gene amplification and dispersion in evolution of great apes and humans.

Journal Article Proc Natl Acad Sci U S A · October 14, 1997 Featured Publication Keratinocyte growth factor (KGF) is a member of the fibroblast growth factor family. Portions of the gene encoding KGF were amplified during primate evolution and are present in multiple nonprocessed copies in the human genome. Nucleotide analysis of a rep ... Full text Link to item Cite

Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing.

Journal Article Int Immunol · August 1997 Point mutations in oncogene products such as ras may create neoantigenic determinants recognizable by T lymphocytes as tumor antigens, that could be marshalled to eliminate a tumor by inducing specific cytotoxic T lymphocytes (CTL) with an appropriate vacc ... Full text Link to item Cite

Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer.

Journal Article Chest · July 1997 Featured Publication BACKGROUND: Small cell lung cancer (SCLC) cells express and secrete gastrin-releasing peptide (GRP) which binds to receptors and stimulates growth of these cells. A murine monoclonal antibody, 2A11, which binds GRP with high affinity, decreased growth of S ... Full text Link to item Cite

Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action.

Journal Article Proc Natl Acad Sci U S A · June 24, 1997 Frizzled polypeptides are integral membrane proteins that recently were shown to function as receptors for Wnt signaling molecules. Here, we report the identification of a novel, secreted 36-kDa protein that contains a region homologous to a putative Wnt-b ... Full text Link to item Cite

Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer.

Journal Article J Clin Oncol · February 1997 PURPOSE: To determine the maximum-tolerated dose (MTD) of paclitaxel administered by 96-hour continuous infusion in combination with cisplatin, to determine if the addition of granulocyte colony-stimulating factor (G-CSF) permits significant paclitaxel dos ... Full text Link to item Cite

Genomic screen for linkage in a family with autosomal dominant chordoma.

Conference AMERICAN JOURNAL OF HUMAN GENETICS · 1997 Cite

Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA.

Journal Article Int J Cancer · September 17, 1996 It has been known that the incidence of p53 mutation is very rare in HBX-positive primary human hepatocellular carcinoma (HCC) tissues. The frequency of p53 mutation, however, in established cell lines with integrated HBV DNA and/or HBX has not been well s ... Full text Link to item Cite

Retreatment of patients surviving cancer-free 2 or more years after initial treatment of small cell lung cancer.

Journal Article Chest · July 1996 STUDY OBJECTIVE: To assess the outcome after retreatment of patients with small cell lung cancer (SCLC) who redevelop small cell cancer (SCC) 2 or more years after initial therapy. DESIGN: Retrospective analysis. SETTING: Single government institution: the ... Full text Link to item Cite

Genetic analysis of second primary lung cancers in patients surviving small cell lung cancer.

Journal Article Clin Cancer Res · July 1996 We performed genetic analysis on 12 second primary non-small cell lung cancers in patients surviving small cell lung cancer to assess the potential contribution of smoking to the development of these tumors. Mutations of TP53 were found in three (25%) tumo ... Link to item Cite

Biology and molecular genetics of lung cancer

Journal Article Seminars in Respiratory and Critical Care Medicine · January 1, 1996 The most extensively characterized autocrine growth loop in lung cancer involves the epidermal growth factor-like family and its receptors. The presence of one or more of the molecules in the tumor specimen is associated with shortened patient survival, mo ... Full text Cite

Candidate cancer vaccines: Oncogenic mutations in ras create hla-a2.1 binding peptides

Journal Article Journal of Investigative Medicine · January 1, 1996 Missense mutations in RAS facilitate neoplastic transformation in a variety of tissues. These mutant proteins are potential antigenic targets of tumor-specific, class I-restricted cytotoxic T lymphocyte responses. Such responses would require that peptides ... Cite

Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage

Journal Article Oncogene · November 2, 1995 The CDKN2 tumor suppressor gene encodes an inhibitor of type D cyclin dependent kinases. CDKN2 is homozygously deleted in approximately 25% of non-small cell lung cancer (NSCLC) cell lines and these deletions are associated with advanced stage cancer. Conf ... Cite

Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.

Journal Article Oncogene · November 2, 1995 The CDKN2 tumor suppressor gene encodes an inhibitor of type D cyclin dependent kinases. CDKN2 is homozygously deleted in approximately 25% of nonsmall cell lung cancer (NSCLC) cell lines and these deletions are associated with advanced stage cancer. Confl ... Link to item Cite

CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines.

Journal Article Int J Cancer · October 9, 1995 Human cervical cancers frequently contain retinoblastoma protein (Rb) that is inactivated by binding with human papilloma virus (HPV) E7 protein or through mutation. The CDKN2 gene encodes p16INK4 which inhibits cdk4-cyclin D phosphorylation of Rb, prevent ... Full text Link to item Cite

TP53 and RAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract.

Journal Article Int J Cancer · August 22, 1995 Patients who initially develop an upper aerodigestive tract cancer have an increased risk of second primary cancers. We examined TP53 and RAS mutations and p53 protein in 21 tumors from 10 patients with upper aerodigestive tract cancer who developed a meta ... Full text Link to item Cite

Biology of small cell lung cancer.

Journal Article Lung Cancer · June 1995 The bombesin-like peptides can function as autocrine growth factors in lung cancer and candidate tumor suppressor genes on chromosomes 3 and 9 play important roles in lung cancer. Bombesin-like peptides can function as mitogens for normal bronchial epithel ... Full text Link to item Cite

Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines.

Journal Article J Natl Cancer Inst · May 17, 1995 Featured Publication BACKGROUND: The CDKN2 gene encodes the human cyclin-dependent kinase 4 inhibitor. This inhibitor protein is believed to be a tumor suppressor that plays an essential role in cell cycle regulation. One half of all cancer cell lines and one fourth of lung ca ... Full text Link to item Cite

Anticancer antibodies for lung cancer.

Journal Article J Clin Oncol · November 1994 Full text Link to item Cite

Small cell lung carcinoma cell lines express mRNA for calcitonin and alpha- and beta-calcitonin gene related peptides.

Journal Article Cancer Lett · June 15, 1994 Calcitonin (CT) and calcitonin gene related peptide (CGRP) are derived from preprohormones encoded by three mRNAs (CT, alpha-CGRP and beta-CGRP) from two genes (CALC1 and CALC2) on chromosome 11. Among 16 small cell lung cancer cell lines examined by RNase ... Full text Link to item Cite

Calcitonin elevation in small cell lung cancer without ectopic production.

Journal Article Am J Respir Crit Care Med · January 1994 To determine the relative contribution of ectopic calcitonin (CT) production versus nonectopic secretion of CT in patients with small cell lung cancer (SCLC), serum and urine immunoreactive CT (iCT) levels of 86 different subjects were measured by radioimm ... Full text Link to item Cite

Genetic mechanisms of solid tumor oncogenesis.

Journal Article Adv Intern Med · 1994 The study of the genetic alterations of tumor suppressor genes and protooncogenes in solid tumors has greatly increased our understanding of cancer biology. These findings have extended epidemiologic associations of carcinogens with certain tumors. Further ... Link to item Cite

Overview of genetic and molecular events in the pathogenesis of lung cancer.

Journal Article Chest · January 1993 Research on dominant oncogenes and tumor suppressor genes has characterized differences in genetic lesions between small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) and identified associations with clinical parameters. More than one half ... Full text Link to item Cite

Overview of genetic and molecular events in the pathogenesis of lung cancer

Journal Article Chest · December 1, 1992 Research on dominant oncogenes and tumor suppressor genes has characterized differences in genetic lesions between small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) and identified associations with clinical parameters. More than one half ... Cite

Emergence of the keratinocyte growth factor multigene family during the great ape radiation.

Journal Article Proc Natl Acad Sci U S A · October 1, 1992 Featured Publication The structural gene for human keratinocyte growth factor (KGF), a member of the fibroblast growth factor family, consists of three coding exons and two introns typical of other fibroblast growth factor loci. A portion of the KGF gene, located on chromosome ... Full text Link to item Cite

The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro.

Journal Article J Virol · July 1992 Virulent, wild-type equine infectious anemia virus (EIAV) is restricted in one or more early steps in replication in equine skin fibroblast cells compared with cell culture-adapted virus, which is fully competent for replication in this cell type. We compa ... Full text Link to item Cite